As such, a common escape mechanism for tumor cells from immune surveillance is by mutations in the antigen presentation machinery, most notably in the JAK/STAT/B2M pathway, which are also enriched among patients with acquired resistance to immunotherapy29,30,32. This evidence concerns the gene B2M and neoplasm.